Vivos Therapeutics has acquired an 11% equity interest in SOD Sciences and a 50% co-ownership of SOD's 'Primed Cell for Chronic Disease' test. This strategic move, paid for with $12 million in Series C Convertible Preferred Stock, aims to expand Vivos's patient reach through a potential joint marketing arrangement with SOD and American Health Associates, targeting a large patient base in assisted living facilities.
Vivos Therapeutics has acquired an 11% fully diluted equity interest in SOD Sciences and a 50% co-ownership interest in SOD's 'Primed Cell for Chronic Disease' test. This transaction, valued at $12 million in preferred stock with no cash involved, is significant as it provides Vivos with a new diagnostic tool and potential access to a large patient population (325,000+ patients at 3,000 facilities) through a joint marketing arrangement with SOD and American Health Associates (AHA). This could be a long-term growth opportunity for Vivos, expanding its reach beyond its current focus on OSA treatment to include early detection of chronic diseases. The short-term impact is likely neutral to positive, as the deal is non-cash and opens up new avenues for revenue. However, the realization of the patient access is contingent on negotiating definitive agreements and approval from AHA's bankruptcy court, posing a key risk.